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Abstract
Background: Hepatocelluar carcinoma (HCC) is one of the most common cancers worldwide and a
major cause of cancer-related mortality. HCC is highly resistant to currently available chemotherapeutic
drugs. Defects in apoptosis signaling contribute to this resistance. Myeloid cell leukemia-1 (Mcl-1) is an
anti-apoptotic member of the Bcl-2 protein family which interferes with mitochondrial activation. In a
previous study we have shown that Mcl-1 is highly expressed in tissues of human HCC. In this study, we
manipulated expression of the Mcl-1 protein in HCC cells by RNA interference and analyzed its impact on
apoptosis sensitivity of HCC cells in vitro.
Methods: RNA interference was performed by transfecting siRNA to specifically knock down Mcl-1
expression in HCC cells. Mcl-1 expression was measured by quantitative real-time PCR and Western blot.
Induction of apoptosis and caspase activity after treatment with chemotherapeutic drugs and different
targeted therapies were measured by flow cytometry and fluorometric analysis, respectively.
Results: Here we demonstrate that Mcl-1 expressing HCC cell lines show low sensitivity towards
treatment with a panel of chemotherapeutic drugs. However, treatment with the anthracycline derivative
epirubicin resulted in comparatively high apoptosis rates in HCC cells. Inhibition of the kinase PI3K
significantly increased apoptosis induction by chemotherapy. RNA interference efficiently downregulated
Mcl-1 expression in HCC cells. Mcl-1 downregulation sensitized HCC cells to different chemotherapeutic
agents. Sensitization was accompanied by profound activation of caspase-3 and -9. In addition, Mcl-1
downregulation also increased apoptosis rates after treatment with PI3K inhibitors and, to a lower extent,
after treatment with mTOR, Raf I and VEGF/PDGF kinase inhibitors. TRAIL-induced apoptosis did not
markedly respond to Mcl-1 knockdown. Additionally, knockdown of Mcl-1 efficiently enhanced apoptosis
sensitivity towards combined treatment modalities: Mcl-1 knockdown significantly augmented apoptosis
sensitivity of HCC cells towards chemotherapy combined with PI3K inhibition.
Conclusion: Our data suggest that specific downregulation of Mcl-1 by RNA interference is a promising
approach to sensitize HCC cells towards chemotherapy and molecularly targeted therapies.
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Background
The incidence of hepatocellular carcinoma (HCC) in
Western countries has experienced a significant increase
over recent years. Currently, HCC ranks among the five
most important causes of cancer-related mortality world-
wide [1]. In Western countries, HCC occurs mainly in
patients with liver cirrhosis and has an annual incidence
of about 2–4 cases per 100,000. In developing countries,
the incidence is approximately 20/100,000. The increas-
ing incidence of HCC is mainly due to the large number
of HCV-seropositive patients. Most patients with HCC
show advanced-stage tumor at the time of diagnosis, and
therefore, curative surgical treatment can only be achieved
in a minority of patients [2]. The therapeutical options for
palliative treatment as well as in patients awaiting liver
transplantation are rare [3]. Therefore, new treatment reg-
imens for patients with advanced HCC are needed.
Defects in apoptosis signaling contribute to tumorigenesis
and chemotherapy resistance of HCC cells. Stabilization
of mitochondrial integrity is a key mechanism for both
the survival of a malignant cell and for its resistance to
chemotherapy [4,5]. A well established family of proteins
that has a significant impact on mitochondrial integrity by
influencing the permeability of the mitochondrial mem-
brane is the Bcl-2 family. Bcl-2 family members can be
roughly subdivided into anti- and pro-apoptotic proteins.
Myeloid cell leukemia-1 (Mcl-1) is an anti-apoptotic
member of the Bcl-2 family, originally identified as an
early induction gene during differentiation of myeloid
leukemia cells [6]. Mcl-1 contains the Bcl-2 homology
(BH) domains BH1-3 and a PEST domain and is a rapidly
inducible protein with a short half life [7-9]. It is
expressed in various tissues including the liver [10]. In
contrast to Bcl-2, Mcl-1 is not only found in mitochon-
drial membranes, but also in the nucleus and cytoplasm
[11]. Several modes of action have been suggested for the
anti-apoptotic activity of Mcl-1. Mcl-1 blocks cytochrome
c-release from mitochondria by interacting with pro-
apoptotic members of the Bcl-2 protein family, e.g. Bim
[12], Bak [13,14], and NOXA [15]. Furthermore, Mcl-1
interacts with truncated Bid and, thereby, inhibits intrin-
sic as well as extrinsic apoptotic signaling [16]. Degrada-
tion of Mcl-1, e.g. by caspase-3, -8 or granzyme B-
mediated cleavage [12], enables proapoptotic Bcl-2 pro-
teins to initiate mitochondrial acitivation.
Mcl-1 has been demonstrated to be highly expressed in
various human tumor specimens, e.g. in multiple mye-
loma, non-small cell lung cancer and liver metastasis of
colorectal cancer [17-19]. In addition, Mcl-1 expression
correlates with disease grade and survival in human
malignancies, e.g. in patients with multiple myeloma or
B-cell non-Hodgkin's lymphoma [20,21]. Moreover, Mcl-
1 expression predicts response to anti-cancer treatment,
e.g. in chronic lymphocytic leukemia or patients with
metastasized colorectal cancer [19,22]. Downregulation
of Mcl-1 leads to sensitization of tumor cells to different
treatment regimens in vitro, as shown for cholangiocarci-
noma, chronic myelogenous leukemia, sarcoma and
malignant melanoma [23-26].
Recently, we and others have shown that Mcl-1 is fre-
quently expressed in tissues of HCC and contributes to
apoptosis resistance [27,28]. In non-tumor liver tissue
adjacent to HCC Mcl-1 immunoreactivity was signifi-
cantly lower [27]. No correlation of Mcl-1 expression with
the underlying liver disease could be detected [28]. We
have also shown that Mcl-1 expression in HCC cells is reg-
ulated by different survival pathways such as the PI3K/
Akt- and MEK1/Erk-pathway [27].
In this study, we analyze the role of the anti-apoptotic Bcl-
2 family member Mcl-1 for the sensitivity of HCC cells
towards different treatment regimens such as chemother-
apy, kinase inhibition and death receptor ligands. We
show that specific downregulation of Mcl-1 by RNA inter-
ference leads to significantly higher apoptosis sensitivity
of HCC cells. Thus, interference with Mcl-1 expression is
an option for the treatment of patients with HCC.
Methods
Reagents and cell lines
The human hepatoma cell lines Hep3B and HepG2 were
grown in MEM, and Huh7 in DMEM (Invitrogen, Karl-
sruhe, Germany), all supplemented with 10% fetal bovine
serum (Biochrom, Berlin, Germany). Reagents were pur-
chased from the following suppliers: LY294002,
PD98059, AG490, Raf I-kinase inhibitor, SU5614 (all sol-
ubilized in dimethyl sulfoxide), cisplatin and mitomycin
C from Calbiochem (Schwalbach, Germany), valproic
acid (VA, orfiril) from Desitin (Hamburg, Germany), 5-
Fluorouracil and SP600125 from Sigma (Deisenhofen,
Germany).
Detection of apoptosis
HCC cell lines were seeded onto 12-well plates. On day 3
(PHH) or day 1 (cell lines) after seeding, cells were treated
as indicated. After the indicated time periods, cells were
collected, washed, and resuspended in lysis buffer con-
taining 0.1% (w/v) sodium citrate, 0.1% (v/v) Triton X-
100 and 50 μg/mL propidium iodide (Sigma). After over-
night incubation at 4°C, nuclei from apoptotic cells were
quantified by flow cytometry according to the method by
Nicoletti et al [29], using a FACS Calibur (BD Biosciences,
Heidelberg, Germany).
Caspase activities
Cells were lysed in buffer containing 20 mM Tris/HCl pH
8.0, 5 mM EDTA, 0.5% Triton X-100 and 1× completeBMC Cancer 2006, 6:232 http://www.biomedcentral.com/1471-2407/6/232
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protease inhibitor cocktail (Roche). Protein concentration
was equilibrated by Dc Protein Assay (Bio-Rad). Lysates
were incubated in reaction buffer (25 mM HEPES pH 7.5,
50 mM NaCl, 10% glycerol, 0.05% CHAPS, and 5 mM
dithiothreitol) in the presence of 50 μM fluorogenic sub-
strate (Biomol, Germany), specific for by caspase-3
(DEVD-AMC) or caspase-9 (Ac-LEHD-AFC). Assays were
performed in black Maxisorb microtiter plates (Nunc,
Germany), and the generation of free AMC or AFC at
37°C after 1 h was measured using a fluorometer plate
reader (Tecan, Germany) set to an excitation wavelength
of 380 nm (AMC and AFC) and an emission wavelength
of 460 nm (AMC) or 505 nm (AFC).
Cell lysis and Western blotting
Cells were lysed by incubation on ice for 15 min in lysis
buffer containing 120 mM NaCl, 50 mM Tris/HCl (pH
8.0), 1 % Nonidet P-40, 1 mM phenylmethylsulfonyl flu-
oride, 25 mM NaF, 0.1% sodium dodecyl sulfate, 100 μM
Na3VO4, 1 mM DTT, and a commercial protease inhibitor
cocktail from Roche Diagnostics (Mannheim, Germany).
Cell debris was removed by centrifugation (10,000 g;
4°C). Proteins were separated by 10% SDS (sodium
dodecyl sulfate)-polyacrylamide gel electrophoresis and
transferred to a Hybond ECL nitrocellulose membrane
(Amersham Pharmacia Biotech, Freiburg, Germany).
Immunodetection was performed using the indicated pri-
mary antibodies: anti-Mcl-1 (Santa Cruz Biotechnology,
Heidelberg, Germany), mouse anti-alpha-Tubulin clone
B-5-1-2 (Sigma). Peroxidase-conjugated antibodies (Santa
Cruz Biotechnology) were applied at a concentration of
40 ng/ml. Bound antibody was visualized using chemilu-
minescent substrate (Perkin-Elmer, Zaventem, Belgium)
and exposure to Fuji Medical X-Ray film.
RNAi for Mcl-1
For small interfering RNA (siRNA)-mediated downregula-
tion of Mcl-1 the following siRNA oligonucleotides were
employed (MWG Biotech, Ebersberg, Germany): 5'-
aaguaucacagacguucucTT-3' (sense) and 5'-gagaacgucugu-
gauacuuTT-3' (antisense). As a non-silencing control
siRNA specific for green fluorescent protein (GFP) was
used: 5'-ggcuacguccaggagcgcaccTT-3' (sense) and 5'-
ggugcgcuccuggacguagccTT-3' (antisense), where capitals
represent DNA-overhangs and lower case letters represent
specific RNA-sequences. Huh7 cells were transiently trans-
fected with Transfectin (Bio-Rad, Hercules, CA, USA)
according to the manufacturer's protocol and analyzed
24–72 h after transfection.
Real-Time Quantitative Polymerase Chain Reaction (RT-
QPCR)
Total RNA from Huh7 cells was extracted using RNeasy
Mini Kit (Qiagen). 1 μg of total RNA was reverse tran-
scribed using an oligo-dT primer and afterwards analyzed
by RT-QPCR using the QuantiTect SYBR Green PCR Kit
(Qiagen) and the following primers: Actin forward: 5'-
GGA CTT CGA GCA AGA GAT GG-3', Actin reverse: 5'-
AGC ACT GTG TTG GCG TAC AG-3', Mcl-1 forward: 5'-
TAA GGA CAA AAC GGG ACT GG-3', and Mcl-1 reverse:
5'-ACC AGC TCC TAC TCC AGC AA-3'. The relative
increase in reporter fluorescent dye emission was moni-
tored. The level of Mcl-1 mRNA, relative to actin, was cal-
culated using the formula: Relative Mcl-1 mRNA
expression = 2^[ct(Mcl-1control)-ct(Mcl-1treated)+ct(Actin-
treated)-ct(Actincontrol)], where ct is defined as the number of
the cycle in which emission exceeds an arbitrarily defined
threshold.
Statistical analysis
All results are expressed as mean + standard error. Data
were analyzed by Student's t test (paired, two sided). P <
0.05 was considered significant.
Results
Low sensitivity of Mcl-1 expressing HCC cells towards 
chemotherapeutic drug-induced apoptosis
Myeloid cell leukemia-1 (Mcl-1) is an important anti-
apoptotic factor for HCC [27,28]. We have previously
shown that different HCC cell lines such as Huh7, Hep3B
and HepG2 show high expression of Mcl-1 [27]. In this
study, we first sought to explore the sensitivity of Mcl-1
expressing HCC cell lines to chemotherapeutic drug-
induced apoptosis. Huh7, Hep3B and HepG2 cells were
treated with different chemotherapeutic drugs, such as
mitomycin C and cisplatin (both drugs used in transarte-
rial chemoembolization (TACE) of HCC [30]), epirubicin
and 5-Fluorouracil (5-FU) (both used for palliative chem-
otherapy [31]). In Huh7 cells, treatment with mitomycin
C, cisplatin, 5-FU and bleomycin for 24 h resulted in
apoptosis rates below 5%. Epirubicin (1 μg/ml), however,
led to apoptosis rates of about 15% after 24 h. After treat-
ment for 48 h, 5-FU, bleomycin and mitomycin C
induced apoptosis in about 20% of Huh7 cells (5-FU,
150–300 μg/ml, bleomycin, 300 μg/ml, and mitomycin
C, 10 μM) (Fig. 1). Cisplatin (1–5 μg/ml) induced apop-
tosis in only 10% of the cells after 48 h. Comparatively
high apoptosis rates were observed after 48 h of epirubicin
treatment (46%, 0.2–1 μg/ml) (Fig. 1).
We have already shown in previous studies that Hep3B
and HepG2 exhibit only low sensitivity towards treatment
with bleomycin and epirubicin [27,32]. In this study, sen-
sitivity of Hep3B and HepG2 cells towards other chemo-
therapeutic drugs such as 5-FU and cisplatin was
comparable to Huh7 (data not shown).BMC Cancer 2006, 6:232 http://www.biomedcentral.com/1471-2407/6/232
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Enhanced apoptosis sensitivity of Mcl-1 expressing HCC 
cells to chemotherapy after inhibition of PI3K, but not 
after inhibition of Jak2, mTOR, MEK1, Src or Raf I kinase
Next, we analyzed whether interference with Mcl-1 expres-
sion could possibly influence the apoptosis sensitivity of
HCC cell lines. One approach to influence Mcl-1 expres-
sion in liver cells is by blocking kinase signaling pathways.
This has been shown for the PI3K/Akt- [33], the MEK1/
Erk- [34] and the Jak2/STAT3 signaling pathways [35]. We
have already shown that inhibition of PI3 kinase reduced
expression of Mcl-1 in Hep3B cells and sensitized cells
towards apoptosis induction by bleomycin [27]. In this
Sensitivity of Huh7 cells towards chemotherapeutic drug-induced apoptosis Figure 1
Sensitivity of Huh7 cells towards chemotherapeutic drug-induced apoptosis. Huh7 cells were treated with 5-FU, 
mitomycin C, epirubicin, or cisplatin for 24 h and 48 h, respectively (concentration as indicated). Cells were then harvested and 
analyzed for apoptosis induction by flow cytometry according to the method of Nicoletti et al. [29]. Assays were performed in 
triplicates and are representative for three independent experiments. Values are means + SD.
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study we tested the effect of PI3K inhibition on Mcl-1
expression and apoptosis sensitivity in the HCC cell line
Huh7. In contrast to Hep3B, even prolonged incubation
of Huh7 cells with the PI3K inhibitor LY29004 for up to
24 h did not markedly reduce Mcl-1 expression in Huh7
cells (Fig. 2A). However, after a short incubation for 1 h,
a slightly reduced Mcl-1 expression level was observed
(Fig. 2A).
PI3K inhibition (LY294002, 50 μM) alone induced apop-
tosis rates of about 20% after 48 h, and significantly
increased chemotherapeutic drug-induced apoptosis: Epi-
rubicin-induced apoptosis was increased from 28 to 62%
(0.2 μg/ml, 48 h, p < 0.01) and 5-FU-induced apoptosis
from 20 to 37% (300 μg/ml, 48 h, p < 0.001) (Fig. 2B).
In addition, we inhibited other signaling pathways which
have been described to influence both the survival of can-
cer cells and the expression of Bcl-2 family proteins.
MEK1/2 is a critical enzyme at the intersection of several
biological pathways involved in cancer growth as part of
the Ras/Raf/MEK/Erk pathway. In a previous study of our
group, inhibition of MEK1 by PD98059 in Hep3B cells
neither influenced Mcl-1 expression nor sensitized to ble-
omycin-induced apoptosis (300 μg/ml, 48 h) [27]. In this
study, we also analyzed the effect of MEK1 inhibition on
Blocking of different protein kinases and its effect on Mcl-1 expression and chemotherapeutic drug-induced apoptosis Figure 2
Blocking of different protein kinases and its effect on Mcl-1 expression and chemotherapeutic drug-induced 
apoptosis. (A) Huh7 cells were treated with the kinase inhibitors LY294002 (25 μM, blocking PI3 kinase), PD98059 (50 μM, 
blocking MEK1), SP600125 (1–100 μM, blocking JNK1), AG1478 (0.5–5 μM, blocking EGF receptor tyrosine kinase), rapamycin 
(50 pM, blocking mTOR kinase) and Raf I-kinase inhibitor (0.1–1 μM) for the time indicated. Whole cell lysates were prepared, 
separated, and immunoblotted with antibodies against Mcl-1 and alpha-tubulin. Blots shown are representative for at least two 
independent experiments. (B) Huh7 cells were treated with LY294002 (25 μM), PD98059 (50 μM), rapamycin (50 pM). After 1 
h of pre-incubation, cells were additionally treated with epirubicin, 5-FU or left untreated for 24 h (concentrations as indi-
cated). Cells were then harvested and analyzed by flow cytometry for apoptosis induction according to Nicoletti et al. [29]. 
Assays were performed in triplicates and are representative for three independent experiments. Values are means + SD. *p < 
0.01, **p < 0.001.BMC Cancer 2006, 6:232 http://www.biomedcentral.com/1471-2407/6/232
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Mcl-1 expression and apoptosis sensitivity in Huh7 cells.
As in Hep3B cells, we found that MEK1 inhibition did not
influence Mcl-1 expression in these cell lines (Fig. 2A).
Neither Mcl-1 expression nor chemotherapeutic drug-
induced apoptosis (as tested for cisplatin, epirubicin and
5-FU) was influenced by MEK1 inhibition (Fig. 2A, 2B,
and data not shown).
The signaling pathways Jak2/STAT3 as well as Src kinase
signaling have been discussed to contribute to apoptosis
sensitivity of carcinoma cells including HCC [36-38]. Nei-
ther inhibition of Jak2 by AG490 (20 μM, 1–6 h) nor inhi-
bition of Src kinases by PP2 (10 μM, 1–6 h) influenced
Mcl-1 expression in Huh7 cells (data not shown). In addi-
tion, PP2 (10 μM) and AG490 (20 μM) had no significant
impact on 5-FU/VA-induced apoptosis of Huh7 cells (5-
FU 150 μg/ml, VA 100 μg/ml, 24 h, data not shown).
Several kinase inhibitors involved in Ras signaling have
entered clinical trials [39]. Raf kinase inhibitors such as
sorafenib have been proved to exert anti-tumoral activity
in patients with advanced HCC [40]. Treatment of Huh7
cells with a Raf I-kinase inhibitor neither altered Mcl-1
expression nor influenced sensitivity towards chemother-
apeutic drug-induced apoptosis (Fig. 2A, and data not
shown). The mTOR protein kinase has emerged as a criti-
cal growth-control kinase and receives stimulatory signals
from Ras and other kinases. mTOR-inhibition showed
anti-tumoral activity in HCC patients [41]. The widely
used mTOR inhibitor rapamycin did not influence Mcl-1
expression or apoptosis sensitivity of Huh7 cells (Fig. 2A,
2B).
Sensitizing HCC cells towards chemotherapeutic drug-
induced apoptosis by RNAi of Mcl-1 expression
HCC cells are rather resistant to chemotherapeutic drug-
induced apoptosis. The Bcl-2 family member Mcl-1 has
been described to contribute to the resistant phenotype in
hepatocellular carcinoma [27,28]. Thus, a potential
approach to sensitize HCC cells to chemotherapy is the
specific knock down of Mcl-1. In this study, we applied
RNA interference to downregulate Mcl-1 expression in the
HCC cell line Huh7. Transfection with Mcl-1 specific
siRNA led to a profound decrease of Mcl-1 expression on
mRNA as well as protein level already 24 h after transfec-
tion and continues for at least 72 h (Fig. 3A). Next, we
tested the effect of Mcl-1 downregulation on chemothera-
peutic drug-induced apoptosis of HCC cells. Mcl-1 down-
regulation by siRNA alone did not induce apoptosis (Fig.
3B). However, Mcl-1 downregulation sensitized Huh7
cells towards a panel of chemotherapeutic drugs including
epirubicin, mitomycin C, and 5-FU (Fig. 3B). For exam-
ple, epirubicin-induced apoptosis was enhanced from 23
to 34% (1 μg/ml, 24 h, p < 0.01) and mitomycin C-
induced apoptosis from 22% to 46% (10 μM, 24 h, p <
0.001). In a previous study, we have shown that 5-FU-
induced apoptosis of hepatoma cells is increased by addi-
tion of histone deacetylase inhibitors such as valproic acid
(VA) [32]. 5-FU/VA-induced apoptosis of Huh7 cells was
increased from 9 to 30% by knockdown of Mcl-1 (5-FU
150 μg/ml, VA 100 μg/ml, 24 h, p < 0.001) (Fig. 3B).
Application of siRNA specific for Mcl-1 only slightly
enhanced cisplatin-induced apoptosis compared to cells
transfected with control siRNA (data not shown). Further-
more, downregulation of Mcl-1 did not sensitize Huh7
cells towards UV irradiation-induced apoptosis (7.5 and
15 mJ/cm2, 24 h; Fig. 3B).
Cleavage and activation of caspases is a central event in
apoptosis pathways. Thus, we also tested the activity of
caspase-3 and -9 after chemotherapy with or without
downregulation of Mcl-1. In cells with knockdown of
Mcl-1, caspase activity was profoundly higher after treat-
ment with chemotherapeutics compared to mock treated
cells. Treatment with epirubicin (1 μg/ml, 24 h), for exam-
ple, resulted in significant higher caspase-3 and -9 activi-
ties compared to epirubicin-treated control cells (Fig. 3C).
Sensitizing HCC cells towards PI3K by specific 
downregulation of Mcl-1
Targeted therapy by kinase inhibitors, such as the Raf
kinase inhibitor sorafenib, is already applied in clinical
trials for the treatment of advanced hepatocellular carci-
noma [40]. In this study, we analyzed the relevance of
Mcl-1 expression for apoptosis induced by different
kinase inhibitors.
Inhibition of PI3 kinase in Huh7 cells by LY294002 alone
induced apoptosis only to a minor extent (Fig. 4). How-
ever, after specific downregulation of Mcl-1 by RNA inter-
ference, apoptosis was induced (17.2% after 24 h, p <
0.001) (Fig. 4). In contrast, neither MEK1 inhibition by
PD98059 (50 μM, 24 h), nor inhibition of Src kinases by
PP2 (10 μM, 24 h) induced apoptosis in cells with down-
regulated Mcl-1 (Fig. 4). In contrary, knockdown of Mcl-1
slightly sensitized HCC cells towards inhibition of mTOR
by rapamycin (5 nM, 24 h, p < 0.01), selective inhibition
of VEGF (Flk-1) and PDGF receptor tyrosine kinases by
SU5614 (15 μM, 24 h, p < 0.01) (Fig. 4) and inhibition of
the Raf I kinase (p < 0.05, 100 nM, 24 h, Fig. 5A).
Epidermal Growth Factor (EGF) is involved in carcinogen-
esis and apoptosis sensitivity of cancer cells. Inhibition of
EGF receptor tyrosine kinase activity by AG1478 (5 μM,
24 h), slightly sensitized cells towards Mcl-1 downregula-
tion (p < 0.001, Fig. 5A).
Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL/Apo2L) exhibits potent antitumor activity on sys-
temic administration and is potentially safe to hepato-BMC Cancer 2006, 6:232 http://www.biomedcentral.com/1471-2407/6/232
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cytes in a monotherapeutic approach [42]. Treatment of
Huh7 cells with TRAIL alone (100 ng/ml, 24 h) did not
induce apoptosis. In addition, no sensitization was
observed by downregulation of Mcl-1 (Fig. 4). However,
in a concentration of 50 ng/ml, TRAIL-induced apoptosis
was slightly enhanced by downregulation of Mcl-1 (Fig.
5A, p < 0.05).
Sensitizing HCC cells towards combined treatment 
modalities after downregulation of Mcl-1
One approach to treat advanced HCC is the combined
application of chemotherapy and protein kinase inhibi-
tors or cytotoxic antibodies [43]. Thus, we tested whether
the effectiveness of combined treatment regimens can be
increased by knockdown of Mcl-1. Knockdown of Mcl-1
Silencing of Mcl-1 expression in HCC cells by RNA interference results in sensitization towards chemotherapy Figure 3
Silencing of Mcl-1 expression in HCC cells by RNA interference results in sensitization towards chemotherapy. 
(A) Huh7 cells were transfected with siRNA specific for Mcl-1 (40 nM) or transfected with siRNA specific for green fluorescent 
protein (GFP) as control. Cells were lysed 24, 48 and 72 h after transfection and analyzed for Mcl-1 expression by Western 
Blot (upper panel). Tubulin expression was used to control equal loading. siRNA concentration was titrated as indicated and 
expression of Mcl-1 and tubulin was analyzed by Western Blot 24 h after transfection (middle panel). 24 h after transfection 
with siRNA (40 nM), total RNA was extracted and analyzed for Mcl-1 mRNA expression by quantitative real-time PCR (lower 
panel). Expression of Mcl-1 was normalized to actin in each sample. Relative Mcl-1 expression was calculated as described in 
the materials and methods section. (B) Huh7 cells were transfected with siRNA specific for Mcl-1 (40 nM, "Mcl-1 siRNA +") or 
transfected with siRNA specific for GFP as control ("Mcl-1 siRNA -"). 24 h after transfection cells were treated with different 
chemotherapeutic drugs for 24 h (mitomycin C, 10 μM, 5-FU, 150 μg/ml (with or without valproic acid, VA, 100 μg/ml) and 
epirubicin, 1 μg/ml). Some cultures were irradiated with UV (7.5 and 15 mJ/cm2, respectively). 24 h later, cells were harvested 
and analyzed by flow cytometry for apoptosis induction according to the method by Nicoletti [29]. Assays were performed in 
triplicates and are representative for at least three independent experiments. Values are means + SD. *p < 0.01, **p < 0.001. 
(C) Cells were incubated for 24 h with epirubicin (1 μg/ml). Caspase-3 (upper panel) and caspase-9 (lower panel) activity were 
measured by fluorometric assays as described in the materials and methods section. Bars = SD.
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Apoptosis sensitivity of HCC cells towards different kinase inhibitors and TRAIL after downregulation of Mcl-1 Figure 4
Apoptosis sensitivity of HCC cells towards different kinase inhibitors and TRAIL after downregulation of Mcl-
1. Huh7 cells were treated for 24 h with different kinase inhibitors (LY294002, 25 μM; PD98059, 50 μM; PP2, 10 μM; rapamy-
cin, 50 pM; SU5614, 15 μM; and TRAIL, 100 ng/ml). Cells were transfected 24 h before with siRNA specific for Mcl-1 (40 nM, 
"Mcl-1 siRNA +") or with siRNA specific for green fluorescent protein as a control (40 nM, "Mcl-1 siRNA -"). Apoptosis was 
determined by FACS analysis according to Nicoletti [29]. Values are means + SD. *p < 0.01, **p < 0.001.
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resulted in enhanced apoptosis induction in Huh7 cells
treated with the PI3K inhibitor LY294002 and chemother-
apeutics. For example, apoptosis induction by treatment
with LY294002 (25 μM) and cisplatin (1 μg/ml, 24 h) was
Mcl-1 interference sensitizes HCC cells towards combined treatment modalities Figure 5
Mcl-1 interference sensitizes HCC cells towards combined treatment modalities. (A) Huh7 cells were transfected 
with siRNA specific for Mcl-1 (grey bars) or transfected with siRNA specific for GFP as control (light bars). After 24 h, cells 
were treated with chemotherapeutic drugs for another 24 h: cisplatin, 1 μg/ml, epirubicin, 200 ng/ml, 5-FU, 150 μg/ml (+ valp-
roic acid (VA), 100 μg/ml), and mitomycin C, 5 μM. Some cultures were pre-incubated for 1 h with the kinase inhibitors 
LY294002 (25 μM, blocking PI3K), PD98059 (50 μM, blocking MEK1), AG1478 (5 μM, blocking EGF receptor tyrosine kinase) 
and a Raf I-kinase inhibitor (100 nM). Apoptosis was assessed by FACS analysis. *p < 0.05, **p < 0.001. n.s., not significant. (B) 
and (C) Huh7 cells were transfected with siRNA (40 nM) as described above and treated 24 h thereafter. In (B), cells were 
treated with 5-FU (150 μg/ml) and VA (100 μg/ml) for 8 or 24 h, as indicated. Cells were harvested and caspase-3 (upper 
panel) or caspase-9 activities (lower panel) were measured by applying caspase-specific fluorogenic substrates as described in 
the materials and methods section. *p < 0.01, **p < 0.001. (C) Cells were treated with 5-FU (150 μg/ml) for 48 h with or with-
out simultaneous treatment with TRAIL as indicated. Apoptosis was measured using flow cytometrical analysis. Values are 
means + SD. *p < 0.05, **p < 0.001, n.s., not significant.
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enhanced from 15% (cells transfected with control
siRNA) to 32% (cells transfected with Mcl-1 siRNA, p <
0.001). The sensitizing effect of Mcl-1 RNA interference
was observed in combination with all chemotherapeutic
agents tested in this setting (epirubicin, 5-FU/VA, mito-
mycin C and cisplatin) (Fig. 5A). Additionally, Mcl-1
downregulation sensitized cells towards chemotherapy
combined with MEK1, Raf I kinase, mTOR, VEFG/PDGF
receptor tyrosine kinase, or EGF receptor tyrosine kinase
inhibition (Fig. 5A, and data not shown). However, apop-
tosis rates were not significantly increased by these inhib-
itors compared to Mcl-1 downregulation and
chemotherapy alone.
No sensitization by Mcl-1 downregulation was observed
in cells treated with 5-FU/VA and the JNK1-inhibitor
SP600125 or the Src kinase inhibitor PP2, respectively
(data not shown). Sensitization of HCC cells towards
treatment-induced apoptosis was accompanied by
enhanced activities of caspase-3 and -9. For example, in
cells co-treated with 5-FU (150 μg/ml), VA (100 μg/ml)
and LY294002 (25 μM) for 24 h, caspase-3 activity was
about 30,000 arbitrary units after 8 h and about 43,000
after 24 h in cells treated with Mcl-1 siRNA vs. 16,000 after
8 h and 24,000 after 24 h in cells treated with control
siRNA (Fig. 5B).
Pre-clinical studies proved that co-treatment of TRAIL and
chemotherapeutic drugs can overcome resistance to
chemotherapy in many cancer types including HCC.
Chemotherapy sensitizes HCC cells to TRAIL partly via
activation of the death inducing signaling complex [44].
In the current study, Mcl-1 downregulation slightly sensi-
tized Huh7 cells towards co-treatment with TRAIL and 5-
FU (50 ng/ml and 150 μg/ml, 24 h, 28.9 vs. 27.4% apop-
tosis, p < 0.05, Fig. 5C).
Discussion
Therapy resistance is a common clinical problem in hepa-
tocellular carcinoma (HCC). In the current study we
applied RNA interference to specifically downregulate the
anti-apoptotic Bcl-2 protein Mcl-1 in HCC cells to over-
come resistance. After Mcl-1 knockdown, HCC cells
proved to be more sensitive towards apoptosis induction
by chemotherapy and molecularly targeted therapy. Our
data suggest that Mcl-1 is a promising target for therapeu-
tic approaches in patients with HCC. Since transgenic
deletion of Mcl-1 in the liver in vivo does not induce apop-
tosis in normal hepatocytes, targeting of Mcl-1 in HCC
cells is likely to be tolerated by the surrounding liver tissue
[45].
HCC is considered highly resistant to chemotherapy. This
is in part due to a high expression rate of drug resistance
genes, including p-glycoprotein, glutathione-S-trans-
ferase, heat shock proteins, and mutations in p53. Addi-
tionally, resistance to apoptosis is a principal mechanism
through which HCC cells are enabled to survive therapy,
since chemotherapy and irradiation kill tumor cells
mainly by induction of apoptosis [46]. In this study, we
first tested the sensitivity of Mcl-1 expressing HCC cells to
a panel of chemotherapeutic drugs. Mitomycin C, 5-FU
and bleomycin treatment of different HCC cell lines only
induced low apoptosis rates (below 5% after 24 h; 10–
20% after 48 h). Cisplatin is widely administered locally
and systemically in the treatment of advanced HCC [30].
However, apoptosis was induced in only 10% of the HCC
cell lines after treatment with cisplatin for 48 h. The
anthracycline derivative epirubicin induced higher apop-
tosis rates (about 45% after 48 h). In line with this,
anthracyclines are currently among the most effective
chemotherapeutic agents against HCC and the most fre-
quently used anticancer drugs for monosystemic treat-
ment of advanced hepatocellular carcinoma [31,47].
However, systemic treatment with anthracyclines alone
mostly failed to demonstrate any survival benefit for HCC
patients [48]. Thus, combination chemotherapy regimens
have been tested or are currently in clinical trials in
patients with advanced HCC. So far, median survival in all
of these studies has been short despite objective
responses.
Several defects in apoptosis signaling cells have been dis-
cussed in the past conferring drug resistance of HCC.
These defects include, among others, stabilization of
mitochondria, alterations in survival signaling and inacti-
vation of death receptor signaling [5]. Anti-apoptotic
members of the Bcl-2 family, such as Bcl-2, Bcl-xL, Bfl-1
and Mcl-1, critically regulate the integrity of mitochondria
and have been shown to prevent apoptosis by anticancer
drugs in vitro [4]. Enhanced expression of anti-apoptotic
Bcl-2 proteins is frequently observed in malignancies of
diverse origin, e.g. Bfl-1 in diffuse large-cell lymphoma
[49] and Bcl-xL in lung adenocarcinoma [50]. Pharmaco-
logical manipulation of Bcl-2 family members appears
therefore efficient in cancer treatment [51].
We have previously shown that Mcl-1 expression is con-
siderably enhanced in human HCC tissue compared to
adjacent non-tumor tissue [27]. Increased Mcl-1 expres-
sion has already been demonstrated for other malignan-
cies, e.g. multiple myeloma and non-small cell lung
cancer [17,18]. Mcl-1 significantly correlates with Bcl-xL
expression in HCC tissue [28]. More studies are required
to fully understand the individual roles of the Bcl-2 pro-
teins and how they cooperate to regulate HCC cell sur-
vival.
Our results demonstrate that a specific knockdown of
Mcl-1 by RNAi sensitizes HCC cells to chemotherapeuticBMC Cancer 2006, 6:232 http://www.biomedcentral.com/1471-2407/6/232
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drugs, such as epirubicin, mitomycin C and 5-FU. These
results extend studies on hematopoietic cells which dem-
onstrate that Mcl-1 prolongs survival after exposure to
chemotherapeutic drugs [52]. Our data also add to studies
on other tumor types such as malignant melanoma and
sarcoma, in which specific downregulation of Mcl-1 has
been shown to sensitize cancer cells to chemotherapeutic
drug-induced apoptosis [25,26].
Direct targeting of Mcl-1 by antisense oligonucleotides
has already been shown to sensitize the HCC cell line
HepG2 as well as lung carcinoma cell lines to cisplatin-
induced apoptosis [18,28]. However, in Huh7 cells, we
did not observe enhanced cisplatin-induced apoptosis
upon depletion of Mcl-1. This effect might be cell line-
specific.
Mcl-1 knockdown also augmented tumor cell death after
inhibition of the pro-survival PI3K/Akt pathway. This
pathway contributes to apoptosis resistance in various
malignancies. Active PI3K generates the phosphorylated
lipid phosphatidylinositol-3,4,5-triphosphate
(PtdIns(3,4,5)P3), leading to the recruitment and activa-
tion of other kinases such as Akt (protein kinase B) to the
plasma membrane. Activated Akt induces strong cellular
survival signals. We have already shown that the PI3K/Akt
pathway induces Mcl-1 expression in human hepatocytes
[33]. In the current study, PI3K inhibition for 48 h led to
apoptosis rates of about 20%. Downregulation of Mcl-1
significantly enhanced apoptosis induced by PI3K inhibi-
tion. Furthermore, Mcl-1 downregulation further aug-
mented apoptosis caused by combination therapy with
PI3K inhibition and chemotherapeutics.
One of the downstream targets of Akt is the serine/threo-
nine kinase mTOR which is a promising candidate target
in the PI3K/Akt pathway in HCC [43]. In the current
study, Mcl-1 downregulation slightly enhanced apoptosis
induction in cells treated with chemotherapy and rapamy-
cin. However, this treatment was not superior to the com-
bination of Mcl-1 downregulation and chemotherapy
without rapamycin.
The Ras/Raf/MEK/ERK pathway is another critical signal-
ing cascade in HCC [38,53]. Approaches to disable the
MEK1/ERK pathway may also sensitize tumor cells to
apoptosis induction. ERK phosphorylates and thereby
activates downstream targets like the transcription factor
c-Jun. In the current study, MEK1 inhibition by PD98059
with or without downregulation of Mcl-1 did not induce
significant apoptosis rates in Huh7 cells. Mcl-1 downreg-
ulation, however, when combined with MEK1 inhibition
and chemotherapy, triggered apoptosis in Huh7 cells.
This treatment, however, did not induce higher apoptosis
rates than Mcl-1 downregulation and chemotherapy
alone.
Mcl-1 downregulation also enhanced apoptosis induction
in cells treated with chemotherapy and Raf I kinase inhi-
bition. Again, apoptosis rates were not higher than after
treatment with Mcl-1 downregulation and chemotherapy
alone. Thus, it still remains elusive, if the combination of
chemotherapy, Mcl-1 RNAi and inhibitors of the Ras/Raf/
MEK/ERK pathway is more efficient than the treatment
with chemotherapy and Mcl-1 RNAi alone.
Targeting receptor tyrosine kinases (RTKs) with small
molecule inhibitors recently emerged as a compelling new
approach to cancer therapy. RTKs are involved in the for-
mation and progression of solid tumors such as HCC.
Many kinase inhibitors currently in clinical trials target
RTKs. For example, EGFR tyrosine kinase inhibitors are
tested in clinical trials in patients with advanced HCC
[54]. HCC tissues show significant expression of EGFR
[54]. In the current study, EGFR tyrosine kinase inhibition
alone did not result in HCC cell death even if combined
with Mcl-1 downregulation. However, combined treat-
ment with Mcl-1 siRNA, 5-FU/valproic acid (VA) and the
EGFR tyrosine kinase inhibitor AG1478 resulted in more
than two-fold enhanced apoptosis rates compared to
treatment with control siRNA, 5-FU/VA and AG1478.
Noteworthy, however, the combined treatment was not
superior to the combination of Mcl-1 siRNA and chemo-
therapy alone.
VEGF receptor tyrosine kinase (VEGFR) is another prom-
ising target for the treatment of HCC. HCCs are vascular-
ized tumors with high expression of VEGF raising the
possibility that agents targeting VEGFR might be of thera-
peutic value. In this study, Mcl-1 knockdown sensitized
HCC cells to the VEGF/PDGF inhibitor SU5614. Mcl-1
downregulation might improve therapeutic regimens tar-
geting VEGF or PDGF signaling in HCC. No sensitizing
effect of Mcl-1 knockdown in HCC cells was observed for
the treatment with JNK1 and Src kinase inhibitors. The
same applied for Jak2 inhibitors, although Jak2 has been
shown to be ubiquitously activated in human HCC [38].
The death receptor ligand TRAIL is another promising
anti-cancer agent. We have previously shown that treat-
ment with TRAIL alone or in combination with chemo-
therapeutic drugs (with the exception of cisplatin) is not
toxic for human hepatocytes [42]. Thus, treatment with
TRAIL and chemotherapeutic drugs is a potential thera-
peutic approach to treatment of HCC. Mcl-1 downregula-
tion has already been shown to sensitize
cholangiocarcinoma cells to TRAIL-induced apoptosis
[23] and CML cells towards treatment with imatinib [24].
We did not observe significant apoptosis rates in Huh7BMC Cancer 2006, 6:232 http://www.biomedcentral.com/1471-2407/6/232
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treated with recombinant TRAIL and Mcl-1 siRNA. How-
ever, cells with downregulated Mcl-1 showed slightly
higher apoptosis rates after treatment with TRAIL (signifi-
cant difference for TRAIL 50 ng/ml). In line with previous
results, 5-FU and TRAIL together induced apoptosis in
Huh7 cells [44]. Again, Mcl-1 downregulation only
sligthly sensitized Huh7 cells to this combinatorial
approach (significant difference for 50 ng/ml).
In this study we applied RNA interference (RNAi) to
knock down Mcl-1 expression. RNAi is a phenomenon in
which genes are specifically silenced at the level of mRNA
degradation [55]. In the current study, transfection of
chemically synthesized siRNA had a fast inhibitory effect
on Mcl-1 expression in HCC cells in vitro. 24 h after trans-
fection of HCC cells with siRNA, Mcl-1 expression was
profoundly reduced. siRNA can also be applied in animals
in vivo by intravenous or local injection. For the use in vivo,
the transit of siRNA to the target cells, e.g. HCC cells, is a
major obstacle. However, RNAi-based approaches have
already shown promising preclinical results in animal
models [56]. In a mouse model of fulminant hepatitis,
intravenous application of siRNA targeting the death
receptor CD95 (APO-1/Fas) was capable of preventing
liver injury [57].
An alternative approach to selectively downregulate Mcl-1
is the application of antisense oligonucleotides (ASO).
ASO are chemically modified stretches of single stranded
DNA designed to bind to a specific mRNA and selectively
suppress its translation. ASOs have already entered phase
III clinical trails for the modulation of the chemosensitiv-
ity of human malignancies. Antisense strategies targeting
anti-apoptotic Bcl-2 family proteins including Mcl-1 have
been successfully applied in various human malignancies
in vitro and in vivo [25,58,59]. In contrast to the results of
the current study, Mcl-1 downregulation by ASO treat-
ment in HCC cell lines resulted in spontaneous apoptosis
without an additional apoptotic stimulus [28]. The reason
for this is elusive. It is not likely due to a more effective
knockdown of Mcl-1 by ASO application: 24 to 72 h after
transfection with Mcl-1 siRNA, virtually no Mcl-1 expres-
sion could be detected by Western blot analysis in our
study. One reason might be the different identity of the
HCC cell lines analyzed in both studies.
The molecular mechanisms that mediate the pro-apop-
totic effect of Mcl-1 downregulation in HCC cells remain
elusive and are subject to further studies. An important
mode of action of Mcl-1 is the interaction with pro-apop-
totic Bcl-2 family members (such as Bim [60], Bak, Bid
and Bax). Heterodimerization of Mcl-1 with proapoptotic
Bcl-2 family members can neutralize their proapoptotic
properties. After knockdown of Mcl-1 by RNAi, levels of
free Bim might be increased which in turn may lead to
activation of Bax. The importance of the Mcl-1-Bim com-
plex for apoptotic signaling has been demonstrated previ-
ously [60]. Elevated levels of free Bim might sensitize cells
to apoptotic stimuli such as chemotherapy. Another
mechanism which would explain the sensitizing effects of
Mcl-1 knockdown would be the release of Bak. Mcl-1 is
known to interact with Bak [13]. This complex can be dis-
rupted by p53. However, since p53 mutations are fre-
quently found in HCC, Mcl-1-Bak interaction might be
more stable in HCC, resulting in a stabilization of mito-
chondria. This might also apply for the p53-/- cell line
Huh7, which we used as a model system for silencing Mcl-
1. However, other mechanisms such as the induction of
Ca2+-signaling by elimination of Mcl-1 (as shown in a
previous study [60]), might also explain the sensitizing
effects of Mcl-1 RNAi.
Numerous genes may provide attractive targets for RNAi
in patients with HCC. This study demonstrates that target-
ing of Mcl-1 by siRNA sensitizes HCC cell lines to chemo-
therapy and molecularly targeted therapy. In the future it
may be promising to target more than one gene involved
in apoptosis signaling, e.g. by a mixture of siRNAs or by
the use of plasmids expressing a number of shRNAs [56].
Conclusion
Our study supports the concept that Mcl-1 is an important
survival factor for hepatocellular carcinoma. Targeting of
Mcl-1 via RNA interference is a potential therapeutic strat-
egy to render HCC cells more sensitive to chemotherapy
and molecularly targeted treatment regimens.
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